Engitix Ltd, a biotechnology company pioneering the use of its proprietary human extracellular matrix (ECM) platform for drug discovery across fibrosis and solid tumours, is delighted to announce the appointment of Sonia Quaratino, M.D., PH.D., to its Board of Directors as an independent non-executive director.
With her impressive professional background and expertise in the field of biotechnology, Dr. Quaratino is a valuable asset to the Engitix team and will be a great asset to the company as it continues to explore new breakthroughs in drug discovery.
Dr. Quaratino is a renowned leader in the fields of immunology and oncology, bringing over 25 years of experience in research and clinical development at both biotechnology and pharmaceutical companies. She currently holds the positions of Chief Medical Officer at Georgiamune INC (USA), Chair of the Scientific and Clinical Advisory Board for STipe Therapeutics, and non-executive director for Circio ASA (formerly TargoVax) and Ichnos Sciences INC.
Not only has she served on multiple boards, but she has also overseen research programmes at leading academic institutions, making her an invaluable asset to the scientific community.
Dr Quaratino is an accomplished medical professional, having held a variety of senior roles in the pharmaceutical industry, academia and clinical research. She recently made the transition to a portfolio career after her role as Chief Medical Officer at Kymab was acquired by Sanofi for $1.1 billion plus milestones in April 2021.
Prior to this, she held positions as Global Clinical Program Leader in Translational Clinical Oncology at Novartis, Senior Medical Director and Immunology Advisor at Merck Serono, and was Professor of Immunology at the University of Southampton. During her time in academia she conducted groundbreaking research in basic science and translational medicine, and her findings have been published in renowned scientific journals.
Dr. Quaratino is a highly accomplished medical professional with a wealth of knowledge and expertise. She obtained her Medical Degree and Doctorate in Hematology-Oncology from the University of Palermo and went on to obtain her Ph.D. in Immunology from Imperial College London. Her dedication and passion for the field of medicine has made her an invaluable asset to the medical community.
Eduardo Bravo, Chairman of the Board of Engitix, expressed his excitement in welcoming Dr. Quaratino to the Board. She brings a wealth of expertise in clinical and commercial development of innovative therapies for cancer and chronic inflammatory diseases.
Her scientific and translational understanding of pathogenic mechanisms in chronic inflammation and cancer, paired with Engitix’s internal and partnered drug discovery programmes in fibrosis and solid tumours, will be an invaluable asset to the company.
Dr. Quaratino is delighted to be appointed as a Non-Executive Director on the Engitix board and is eager to make a meaningful contribution towards the company’s strategic development. He is highly impressed with Engitix’s ECM platform, hailing its potential to expedite the identification and validation of new targets in the development of ground-breaking therapies for fibrotic diseases and solid tumours.
About Engitix Ltd
Engitix is revolutionizing drug discovery with its pioneering human extracellular matrix (ECM) platform, allowing for more physiologically relevant human in vitro models. This is paving the way for the development of more advanced treatments and more accurate predictions of therapeutic efficacy.
To accelerate its internal drug development programmes, Engitix has a strategic drug discovery partnership with Dompé farmaceutici, leveraging their AI-enabled high performance computing platform, Exscalate.
They also have collaborations with Takeda, focusing on advanced fibrotic liver diseases such as NASH, as well as fibrostenotic Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis.
Engitix, based in Westworks, White City Place, London, is revolutionizing the healthcare industry. Supported by impressive investors such as Netherton Investments (a fund investing on behalf of Mike Platt) and Dompé farmaceutici S.P.A., the company has already secured more than $60 million in equity.
This has allowed them to commercialize cutting-edge research from the Institute for Liver and Digestive Health, Division of Medicine, University College London (UCL). With this funding, Engitix is working to bring innovative healthcare solutions to the public.